ADx NeuroSciences

Foundation date

16/09/2011

Sector

#Biotechnology - Therapeutics

Subsector

We create tailor-made antibodies and assays to quantify unique biomarkers in a wide variety of neurodegenerative diseases and conditions such as Alzheimer’s disease, Parkinson’s disease and traumatic brain injury. Our assays enable early detection before symptoms appear, providing valuable information from the drug development phase up to clinical practice, to improve the life of patients.

Upcoming events

Latest news

  • Latest field trials validate strength of Biotalys’ first biocontrol Evoca

    Thursday May 19th 2022

  • Belgian biotech in European Top-3 despite turbulent times

    Wednesday May 18th 2022

  • KU Leuven announces collaboration and license agreement with Gilead Sciences for the development of new antivirals against the respiratory syncytial virus

    Wednesday May 18th 2022